INTRODUCTION

Lung cancer is the main cause of cancer-related death in the world.1 More than 75% of lung cancer patients are diagnosed as advanced disease, which makes the 5-year survival rate less than 15%.2 The disadvantage of carcinoembryonic antigen (CEA) is poor sensitivity and specificity in the diagnosis of early lung cancer.3 Therefore, more research is needed to find new biomarkers in order to diagnose and predict the progress of lung cancer.

Macrophage inhibitory cytokine-1 (MIC-1) is a secretory protein of the transforming growth factor-β family and is involved in carcinogenesis-related processes, including proliferation, migration, apoptosis and angiogenesis.4-6 Previous studies have found the value of serum MIC-1 level in the diagnosis of colorectal cancer, prostate cancer, pancreatic cancer and so on.7-10 Recently, it has been reported that serum MIC-1 may be a potential biomarker in NSCLC.11,12 However, the relationship between serum MIC-1 and the progression of NSCLC and the effect of MIC-1 on the NSCLC survival have not been fully evaluated.

In this study, we investigated the relationship between serum MIC-1 and clinicopathological features and patients’ survival. The results showed that serum MIC-1 could be used as a biomarker for the diagnosis and prognosis of NSCLC.

METHODS

2.1 Patients

This was a prospective trial. 296 NSCLC patients (aged 26-77 years) and 240 gender and age-matched healthy controls (aged
were recruited. The patient data were collected, including age, gender, smoking, histological type, grade, stage and outcome. Follow-up information is obtained through telephone survey or WeChat. The last follow-up was on 20 February 2019. Progression-free survival (PFS) was defined as the time interval between the date of diagnosis and the date of recurrence. Overall survival (OS) was defined as the time interval between the date of diagnosis and the date of death.

The study protocol was approved by the Ethics Committee of the Nanjing Chest Hospital. All patients provided written informed consent before enrolment.

2.2 | Measurement of serum MIC-1 and CEA levels

Serum samples were taken from each person prior to the start of the treatment. The sensitive internal sandwich ELISA was used to detect the serum MIC-1 levels. The CEA levels were measured by electrochemiluminescence immunoassay on Roche Elecsys 1010 Analyzer (Roche Diagnostics). All the samples were ignored by the technicians running the tests.

2.3 | Statistical analysis

Statistical software (SPSS for Windows, version 18) was used for the analysis. The Mann-Whitney U test was used to determine the difference between the two groups. The cut-off value of the serum concentrations of parameters was calculated using a receiver operating characteristic (ROC) curve. Univariate analysis was performed using the Kaplan-Meier method and the log-rank test. Multivariate analysis was conducted to determine an independent impact on survival using the Cox proportional hazard method. \( P < .05 \) was considered statistically significant.

**FIGURE 1** ROC curves for the serum MIC-1 (A) and CEA (B) and MIC-1 + CEA (C) in differentiating NSCLC patients and healthy controls. The areas under the curve of serum MIC-1, CEA and MIC-1 + CEA were 0.906, 0.776 and 0.930, respectively.

**FIGURE 2** Kaplan–Meier survival curves for PFS and OS in patients with MIC-1–positive and MIC-1–negative NSCLC. Log-rank test determined that the PFS (A) and OS (B) in positive MIC-1 patients were significantly shorter than those in the negative MIC-1 patients (\( P = .015, P = .004 \)).
## RESULTS

### 3.1 Serum levels of MIC-1 and CEA in NSCLC patients and healthy controls

The serum levels of MIC-1 in NSCLC patients were higher than those of the controls ($1582.31 \pm 473.01$ pg/mL vs $507.71 \pm 107.64$ pg/mL, $P < .001$). The serum CEA levels of NSCLC patients were also higher than those of the controls ($29.78 \pm 7.71$ ng/mL vs $3.36 \pm 1.25$ ng/mL, $P < .001$).

### 3.2 Diagnostic value of MIC-1 and CEA in NSCLC patients

The ROC curve was used to calculate the sensitivity of the marker in separating NSCLC patients from healthy controls. As shown in Figure 1A, an area under the curve (AUC) value for serum MIC-1 reached 0.906 (confidence interval (95% CI): 0.842-0.971). With a cut-off value of 1000 pg/mL, the sensitivity, specificity, accuracy, positive predictive value and negative predictive value of serum MIC-1 were 63.5%, 95.0%, 77.6%, 94.0% and 67.9%, respectively. These results indicated that serum MIC-1 is a valuable biomarker for the diagnosis of NSCLC.

Detection of CEA and analysis of its diagnostic value were analysed. The area under the CEA ROC was 0.776. It was lower compared with the areas of MIC-1 (Figure 1B). With a cut-off value of 5.0 ng/mL, CEA had a sensitivity of 47.3%, a specificity of 93.3%, an accuracy of 67.9%, a positive predictive value of 89.7% and a negative predictive value of 58.9%. The sensitivity of MIC-1 was higher compared with CEA.

The diagnostic value of MIC-1 combined with CEA in NSCLC was further analysed. The results showed that the combined detection of these two indices had a sensitivity of 77.0% and a specificity of 95.8%. The combination of MIC-1 and CEA had better sensitivity and specificity than MIC-1 and CEA alone (Figure 1C).

### 3.3 Association between MIC-1 levels and clinicopathological characteristics

The relationship between serum MIC-1 levels and clinicopathological characteristics of lung cancer was analysed. MIC-1 levels were correlated with TNM stage ($P = .001$), tumour differentiation ($P = .001$) and lymph node metastasis ($P = .004$).

### 3.4 Prognostic value of serum MIC-1 levels for NSCLC patients

Univariate analysis showed that serum MIC-1 levels were correlated with OS ($P = .005$) and PFS ($P = .004$, Table 1). In multivariate analysis,

| Characteristics | Univariate | Multivariate |
|-----------------|------------|--------------|
| PFS             |            |              |
| Gender (male vs female) | 1.175 (0.694-1.990) | .549 | 0.987 (0.844-1.15) | .866 |
| Age (<60 vs ≥60) | 0.887 (0.722-1.090) | .255 | 0.689 (0.351-1.35) | .279 |
| Histological type (SCC vs ADC) | 0.721 (0.385-1.347) | .305 | 0.822 (0.353-1.91) | .650 |
| Differentiation (well-moderate vs poor) | 0.671 (0.346-1.320) | .238 | 1.134 (0.483-2.66) | .773 |
| TNM stage (I-II vs III-IV) | 1.016 (1.002-1.029) | .0021 | 1.834 (1.053-3.19) | .032 |
| Lymph node metastasis ($N_0$ vs $N_{1-3}$) | 1.940 (0.767-4.909) | .162 | 1.316 (0.838-2.06) | .233 |
| MIC-1 (negative vs positive) | 2.230 (1.288-3.860) | .004 | 2.881 (1.460-5.68) | .002 |
| OS              |            |              |
| Gender (male vs female) | 1.016 (0.570-1.812) | .957 | 0.755 (0.390-1.46) | .404 |
| Age (<60 vs ≥60) | 1.044 (0.474-2.302) | .914 | 1.270 (0.636-2.53) | .498 |
| Histological type (SCC vs ADC) | 0.690 (0.245-1.943) | .483 | 2.107 (0.731-6.60) | .167 |
| Differentiation (well-moderate vs poor) | 1.544 (0.640-3.727) | .334 | 1.004 (0.606-1.66) | .987 |
| TNM stage (I-II vs III-IV) | 1.303 (1.261-1.346) | .001 | 1.321 (1.278-1.36) | .001 |
| Lymph node metastasis ($N_0$ vs $N_{1-3}$) | 1.904 (0.627-5.780) | .256 | 1.013 (0.366-2.80) | .980 |
| MIC-1 (negative vs positive) | 2.425 (1.314-4.475) | .005 | 2.247 (1.246-4.05) | .007 |

Abbreviations: ADC, adenocarcinoma; CI, confidence interval; HR, hazard ratio; OS, overall survival; PFS, progression-free survival; SCC, squamous cell carcinoma.

*Statistically significant difference ($P < .05$)
MIC-1–positive was significantly correlated with shorter PFS and OS ($P=.002$ and $P=.007$). The Kaplan-Meier survival curve further confirmed that PFS and OS of NSCLC patients with MIC-1–positive were significantly shorter than those of NSCLC patients with MIC-1–negative (Figure 2).

4 | DISCUSSION

Some studies have shown that MIC-1 can be used as a diagnostic marker for some types of tumours. However, the value of serum MIC-1 level in the diagnosis and prognosis of NSCLC has not been fully elucidated. In this study, the levels of MIC-1 in NSCLC were higher than those in healthy controls. The diagnostic sensitivity and specificity of MIC-1 were 63.5% and 95.0% in NSCLC patients. The results showed that MIC-1 was valuable in the diagnosis of NSCLC. In addition, we found that the levels of MIC-1 were significantly correlated with lymph node metastasis, tumour differentiation and TNM stage, suggesting that MIC-1 may be an indicator of tumour progression in NSCLC patients.

To further analyse the diagnostic value of MIC-1 combined with CEA in NSCLC. The results showed that the combination of MIC-1 and CEA has better diagnostic value than the single index. This may provide a new method for the diagnosis of NSCLC.

Previous studies have shown that the expression of MIC-1 is related to the prognosis of lung cancer. Our study showed that MIC-1–positive was significantly related to the decrease in PFS and OS. The Kaplan-Meier survival curve further illustrates this relationship. It is suggested that the determination of serum MIC-1 level is helpful to predict the prognosis of NSCLC patients.

Several limitations of our study warrant discussion. First, we performed the study at a single centre with relatively small sample size. Second, the expression of MIC-1 in serum of lung cancer patients was detected, but the expression of MIC-1 in lung cancer tissues was not detected. Third, the specific mechanism of the relationship between MIC-1 expression and NSCLC was lacking. Further perspective trial should be performed.

In conclusion, our results suggest that serum MIC-1 may be a valuable biomarker for the diagnosis and prognosis of NSCLC.

ACKNOWLEDGEMENTS

The study was supported by the Major Program of Nanjing Medical Science and Technique Development Foundation (ZKX17044).

CONFLICT OF INTEREST

The authors declare no conflicts of interest in this work.

AUTHOR CONTRIBUTIONS

Chunhua Xu: Conceptualization (equal); Writing-original draft (equal). Li Li: Methodology (equal); Writing-original draft (equal). Wei Wang: Methodology (equal). Qian Zhang: Formal analysis (equal); Resources (equal). Xiwei Zhang: Conceptualization (equal). Rusong Yang: Methodology (supporting).

DATA AVAILABILITY STATEMENT

All data generated or analysed during this study are included in this article.

ORCID

Chunhua Xu https://orcid.org/0000-0001-8728-2183

REFERENCES

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7-30.
2. Xu CH, Sheng ZH, Hu HD, et al. Elevated expression of Cripto-1 correlates with poor prognosis in non-small cell lung cancer. Tumour Biol. 2014;35:8673-8678.
3. Okamura K, Takayama K, Izumi M, et al. Diagnostic value of CEA and CYFRA 21–1 tumor markers in primary lung cancer. Lung Cancer. 2013;80:45-49.
4. Huang M, Narita S, Inoue T, et al. Diet-induced macrophage inhibitory cytokine-1 promotes prostate cancer progression. Endocr Relat Cancer. 2013;21:39-50.
5. Choi HJ, Kim J, Do KH, et al. Enteropathogenic escherichia coli-induced macrophage inhibitory cytokine 1 mediates cancer cell survival: an in vitro implication of infection-linked tumor dissemination. Oncogene. 2013;32:4960-4969.
6. Mimeault M, Johansson SL, Batra SK. Marked improvement of cytotoxic effects induced by docetaxel on highly metastatic and androgen-independent prostate cancer cells by downregulating macrophage inhibitory cytokine-1. Br J Cancer. 2013;108:1079-1091.
7. Mehta RS, Chong DQ, Song M, et al. Association between plasma levels of macrophage inhibitory cytokine-1 before diagnosis of colorectal cancer and mortality. Gastroenterology. 2015;149:614-622.
8. Li J, Veitri RW, Yuan Z, et al. Macrophage inhibitory cytokine-1 biomarker serum immunoassay in combination with PSA is a more specific diagnostic tool for detection of prostate cancer. PLoS One. 2015;10:e0122249.
9. Zhou YF, Xu LX, Huang LY, et al. Combined detection of serum UL16-binding protein 2 and macrophage inhibitory cytokine-1 improves early diagnosis and prognostic prediction of pancreatic cancer. Oncol Lett. 2014;8:2096-2102.
10. Brown DA, Hance KW, Rogers CJ, et al. Serum macrophage inhibitory cytokine-1(MIC-1/GDF15): a potential screening tool for the prevention of colon cancer? Cancer Epidem Biomarkers Prev. 2012;21:337-346.
11. Liu Y, Wang X, Wang T, et al. Macrophage inhibitory cytokine-1 (MIC-1) as a biomarker for diagnosis and prognosis of stage I-II non-small cell lung cancer. Zhongguo Fei Ai Za Zhi. 2016;19:207-215.
12. Liu YN, Wang XB, Wang T, et al. Macrophage inhibitory cytokine-1 as a novel diagnostic and prognostic biomarker in stage I and II non-small cell lung cancer. Chin Med J. 2016;129:2026-2032.

How to cite this article: Xu C, Li L, Wang W, Zhang Q, Zhang X, Yang R. Serum macrophage inhibitory cytokine-1 as a clinical marker for non–small cell lung cancer. J Cell Mol Med. 2021;25:3169–3172. https://doi.org/10.1111/jcmm.16360